US20220202713A1 - Curcumin Solubilisate - Google Patents
Curcumin Solubilisate Download PDFInfo
- Publication number
- US20220202713A1 US20220202713A1 US17/698,389 US202217698389A US2022202713A1 US 20220202713 A1 US20220202713 A1 US 20220202713A1 US 202217698389 A US202217698389 A US 202217698389A US 2022202713 A1 US2022202713 A1 US 2022202713A1
- Authority
- US
- United States
- Prior art keywords
- solubilisate
- curcumin
- fnu
- polysorbate
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 146
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 73
- 239000004148 curcumin Substances 0.000 title claims abstract description 73
- 229940109262 curcumin Drugs 0.000 title claims abstract description 72
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract description 14
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 14
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 14
- 229940068968 polysorbate 80 Drugs 0.000 claims abstract description 14
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract description 11
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 11
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 11
- 239000000693 micelle Substances 0.000 claims abstract description 10
- 229940068977 polysorbate 20 Drugs 0.000 claims abstract description 10
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 210000002381 plasma Anatomy 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 13
- 238000010790 dilution Methods 0.000 claims description 11
- 239000012895 dilution Substances 0.000 claims description 11
- 238000005259 measurement Methods 0.000 claims description 10
- 229930153442 Curcuminoid Natural products 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 5
- 239000007903 gelatin capsule Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 14
- 239000007788 liquid Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 239000008601 oleoresin Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 241000407170 Curcuma Species 0.000 description 2
- 235000014375 Curcuma Nutrition 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000020241 curcumin extract Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0053—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/56—Flavouring or bittering agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/40—Colouring or decolouring of foods
- A23L5/42—Addition of dyes or pigments, e.g. in combination with optical brighteners
- A23L5/43—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2112—Curcumin, turmeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Definitions
- Curcumin is a turmeric extract that has been well known around the world for 5 decades, through the publication of numerous study results, as a spice, a food coloring (E100), as well as a medicament in traditional medicine, and in recent decades in mainstream medicine, as an effective active substance in immunology, osteogenesis, angiogenesis, neurogenesis, and carcinogenesis.
- Curcumin is offered in numerous end products (nutritional supplements), such as in capsules or in liquid cloudy beverages, in its native form (powder), or combined with auxiliary substances such as oil, glycerin, ethanol, phospholipids or lecithin, cyclodextrin, gum arabic, gelatins, pectins, sugar esters of fatty acids, or saponins.
- auxiliary substances such as oil, glycerin, ethanol, phospholipids or lecithin, cyclodextrin, gum arabic, gelatins, pectins, sugar esters of fatty acids, or saponins.
- these formulations are not transparent, do not result in an aqueous clear solution, and have extremely low absorption, i.e., bioavailability.
- curcumin for producing carrier systems, for example emulsions or liposomes
- curcumin is dissolved in a lipophilic phase and stabilized in droplet form in an aqueous environment
- liposomes the curcumin may be held in a phospholipid layer.
- bioavailability may be increased by up to 50%, these types of formulations such as liposomes are extremely unstable mechanically, and also are not resistant to the environment in the stomach.
- Curcumin has attracted special attention in mainstream medicine, in particular in conjunction with neurogenesis (Alzheimer's disease, among others) and carcinogenesis (cancer). To allow preventative action to be taken against these primarily age-related common ailments, which are beginning to have alarming economic impacts, it is an object of the invention to optimize the absorption, i.e., bioavailability, of curcumin by means of an appropriate, suitable formulation. It is a further object of the invention to achieve a stable, homogeneous fine distribution of curcumin in the corresponding end products, such as dietary and nutritional supplements.
- the invention provides a micellar curcumin formulation, on the basis of which bioavailability that is at least 230 times higher in comparison to native curcumin has been established in a human study.
- the invention provides a solubilisate consisting of curcumin in a quantity of less than or equal to 10% by weight, preferably less than or equal to 7.5% by weight, particularly preferably 6% by weight, and at least one emulsifier having an HLB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin is between 5 nm and 40 nm, preferably between 6 nm and 20 nm, particularly preferably between 7 nm and 10 nm.
- FIG. 1 shows photographs of curcumin formulation samples.
- High loading of the micelles with curcumin may thus be advantageously achieved without the micelles bursting and the curcumin being released as sediment upon dilution with water.
- the transparent, completely stable water-soluble curcumin formulation according to the invention without the above-mentioned auxiliary substances such as in soft and hard gelatin capsules, has stable transparency and also greatly improved bioavailability, independently of pH, in gelatin-free capsules (hard and/or soft) and in beverages or liquid, water-based end products.
- Products having such transparency and water solubility, but also in particular such a high bioavailability of the curcumin formulation are in urgent demand by the relevant industry for innovative products as a capsule filling and as transparent curcumin beverages.
- a curcumin formulation which meets these requirements has not existed heretofore.
- the particularly small size of the micelles in the solubilisate according to the invention results in a clear, permanently transparent product.
- the narrow particle size distribution also contributes to this end, since the diameter distribution of the micelles ranges only from approximately 4 nm to approximately 30 nm.
- the particle size distribution of the micelles was measured according to the principle of dynamic light scattering in a 180° backscattering system, using laser light having a wavelength of 780 nm. Due to the small particle sizes, the formation of a liquid which is clear, in particular for perception by the human eye, is advantageously achieved. The clarity of the solubilisate may also be represented by its low turbidity.
- the solubilisate according to the invention is further characterized in that the total curcuminoid concentration in human blood plasma, measured one hour after oral administration of 500 mg curcumin in the form of the solubilisate, is approximately
- the human study on which these values are based was conducted on 24 healthy persons between 19 and 29 years of age, who received a single oral dose of 500 mg native curcumin or curcumin in the form of the solubilisate according to the invention. Blood samples were withdrawn at various times over a period of 24 hours after the curcumin was taken. To minimize the possible concurrent influence of digested food, the test subjects were served standardized meals. One hour after taking the curcumin in native form, less than 1 nmol/l plasma was measured; 8 hours after administration, 2.4 nmol/l was measured; and 24 hours after administration, 2.4 nmol/l was measured.
- curcumin from the solubilisate according to the invention one hour after administration, 1,964 nmol/l was measured in the blood plasma; 8 hours after administration, 307.1 nmol/l was measured; and 24 hours after administration, 67.7 nmol/l was measured.
- a solubilisate containing 66.5% by weight curcumin was used (the commercial product “6% NovaSOL Curcumin” of the applicant).
- the curcumin concentration in the blood plasma showed increases by a factor between 36 and 2800 as a result of the formulation as solubilisate according to the invention, compared to native curcumin.
- the area under the curve of the total curcumin concentration in the blood plasma (area under the total curcumin plasma concentration-time curve (AUC)), measured over a period of 24 hours, was 42.6 nmol h/L for administration of native curcumin, and 9,821.4 nmol h/L for administration of the solubilisate according to the invention.
- AUC total curcumin plasma concentration-time curve
- the bioavailability of the 66.5% curcumin solubilisate is much better than that of the native form. Viewed as the plasma AUC over 24 hours, the bioavailability as a result of the formulation according to the invention of the solubilisate is approximately 230 times higher.
- the turbidity of the solubilisate according to the invention is less than 30 FNU, preferably less than 20 FNU, and particularly preferably is in the range between 0.5 FNU and 2 FNU, determined by scattered light measurement with infrared light according to the requirements of the ISO 7027 standard at a dilution of the solubilisate in water in a ratio of 1:1000.
- the solubilisate according to the invention maintains this low turbidity after 24 hours storage at 21° C. and pH 7, as well as after 1 hour storage at 37° C. and pH 1.1, i.e., under storage conditions on the one hand at room temperature in aqueous dilution, and on the other hand, during passage through the stomach. Therefore, according to the present knowledge of the inventor, the curcumin in the solubilisate according to the invention is still present in the form of the stable, very small micelles even after passage through the stomach, and may therefore by absorbed particularly well in the further digestive tract.
- the turbidity measuring devices are calibrated with a standard suspension.
- the indication is provided not in the form of the measured light intensity, but, rather, as the concentration of the calibration suspension.
- the indication thus signifies that the liquid in question has caused the same light scattering as the standard suspension of the indicated concentration.
- the internationally established turbidity standard is formazin.
- the most commonly used units are “FNU” (formazin nephelometric units). This is the unit that is used, for example, in water treatment for the measurement at 90° according to the requirements of the ISO 7072 standard.
- the turbidity of the solubilisate according to the invention is less than 30 FNU, preferably less than 20 FNU, and is particularly preferably in the range between 0.5 FNU and 2 FNU, determined by scattered light measurement with infrared light according to the requirements of the ISO 7027 standard at a dilution of the solubilisate in water in a ratio of 1:1000.
- the solubilisate according to the invention may contain up to 5% by weight water and/or between 12% by weight and 20% by weight glycerin.
- the solubilisate according to the invention may be easily provided in capsules for oral administration, since it does not attack the capsules.
- the invention thus also provides a capsule filled with the solubilisate, wherein the capsule may be formed as a soft gelatin capsule or hard gelatin capsule, or as a soft gelatin-free capsule or as a hard gelatin-free capsule.
- An additional administration form is a fluid containing the solubilisate according to the invention, wherein the fluid may be a food, a beverage, a cosmetic product such as a cream, lotion, or salve in particular, or a pharmaceutical product.
- the fluid may comprise an aqueous dilution of the solubilisate.
- the usability of the according to the invention in a fluid is not bound to its viscosity; the solubilisate may likewise be incorporated into hydrophilic as well as lipophilic media.
- the particle size measurements were carried out using a ParticleMetrix NANOTRAC backscattering particle analyzer.
- the measuring principle is based on dynamic light scattering (DLS) in a 180° heterodyne backscattering system. In this geometry, a portion of the laser beam is mixed with the scattered light. This has the same positive effect with regard to the signal/noise ratio as the superimposition of all light wavelengths in a Fourier spectrometer. The color of the sample has no influence on the quality of the measurement.
- the measurements were carried out in a 1:1000 aqueous dilution. To this end, the solubilisate was dissolved in water with stirring. The solubilisate is soluble in water, in which it is completely clear. This solution is stable and transparent.
- the 70 g contains 95% curcumin, i.e., 66.5 g of curcumin.
- curcumin powder for example Oleoresin Turmeric 95% (curcumin powder), Jupiter Leys, or Curcumin BCM-95-SG, Eurochem, or Curcumin BCM-95-CG, Eurochem, or Curcuma Oleoresin 95%, Henry Lamotte.
- the polysorbate 80 is heated to approximately 48° C. to approximately 52° C.
- the curcumin powder is slowly added to the polysorbate 80, with stirring. During the addition of the curcumin powder, further heating to approximately 87° C. to approximately 91° C. is carried out.
- the resulting solubilisate is cooled to below approximately 60° C., and is then ready for filling.
- the solubilisate is yellow-orange to reddish, very dark, intensely colored, and transparent.
- the curcumin portion may be increased to approximately 10% by weight at the expense of the polysorbate 80 portion.
- the solubilisate Only 894 g polysorbate 20 and 106 g 95% curcumin powder are used for producing the solubilisate.
- the 106 g contains 95% curcumin, i.e., 100.7 g of curcumin.
- curcumin powder for example Oleoresin Turmeric 95% (curcumin powder), Jupiter Leys, or Curcumin BCM-95-SG, Eurochem, or Curcumin BCM-95-CG, Eurochem, or Curcuma Oleoresin 95%, Henry Lamotte.
- Oleoresin Turmeric 95% curcumin powder
- Jupiter Leys or Curcumin BCM-95-SG, Eurochem
- Curcumin BCM-95-CG Eurochem
- Curcuma Oleoresin 95% Henry Lamotte.
- the polysorbate 20 is heated to approximately 63° C. to approximately 67° C.
- the curcumin powder is slowly added to the polysorbate 20, with stirring. During the addition of the curcumin powder, further heating to approximately 83° C. to approximately 87° C. is carried out. The resulting solubilisate is slowly cooled to below approximately 45° C., and is then ready for filling.
- the solubilisate is yellow-orange to reddish, very dark, intensely colored, and transparent.
- the curcumin portion may be varied at the expense of the polysorbate 80 portion.
- FIG. 1 Photographs of samples of various curcumin formulations are shown in appended FIG. 1 .
- the left side of the illustration shows the samples 24 hours after addition to water at a temperature of 21° C., under neutral conditions (pH 7).
- the right side of the illustration shows the samples under physiological conditions 1 hour after addition to water at a temperature of 37° C., under conditions as in the stomach (pH 1.1). In each case, enough water was added to the starting preparations to give a curcumin concentration of 11.4 g/L in the illustrated sample.
- Curcumin extract native form, powder, 95% curcumin (BCM 95). 12 g of the powder was introduced into 1 liter of water.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A solubilize composed of curcumin in a quantity of less than or equal to 10% by weight, preferable less than or equal to 7.5% by weight, particularly preferable 6% by weight, and at least one emulsifier having an HLB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin in between 5 nm and 40 nm, preferable between 6 nm and 20 nm, particularly preferable between 7 nm and 10 nm.
Description
- This application is a continuation of U.S. application Ser. No. 14/653,560, filed on Jun. 18, 2015, which is a National Stage application under 35 U.S.C. § 371 of International Application No. PCT/EP2013/001427, filed on May 15, 2013, which claims benefit of German Application No. 20 2012 012 130.8, filed on Dec. 19, 2012, the contents of which are hereby incorporated by reference in their entirety.
- Curcumin is a turmeric extract that has been well known around the world for 5 decades, through the publication of numerous study results, as a spice, a food coloring (E100), as well as a medicament in traditional medicine, and in recent decades in mainstream medicine, as an effective active substance in immunology, osteogenesis, angiogenesis, neurogenesis, and carcinogenesis.
- Curcumin is offered in numerous end products (nutritional supplements), such as in capsules or in liquid cloudy beverages, in its native form (powder), or combined with auxiliary substances such as oil, glycerin, ethanol, phospholipids or lecithin, cyclodextrin, gum arabic, gelatins, pectins, sugar esters of fatty acids, or saponins. However, it is problematic that these formulations are not transparent, do not result in an aqueous clear solution, and have extremely low absorption, i.e., bioavailability.
- The use of further components in addition to curcumin for producing carrier systems, for example emulsions or liposomes, is known for increasing the bioavailability. Whereas in emulsions the curcumin is dissolved in a lipophilic phase and stabilized in droplet form in an aqueous environment, in liposomes the curcumin may be held in a phospholipid layer. Although the bioavailability may be increased by up to 50%, these types of formulations such as liposomes are extremely unstable mechanically, and also are not resistant to the environment in the stomach.
- Curcumin has attracted special attention in mainstream medicine, in particular in conjunction with neurogenesis (Alzheimer's disease, among others) and carcinogenesis (cancer). To allow preventative action to be taken against these primarily age-related common ailments, which are beginning to have alarming economic impacts, it is an object of the invention to optimize the absorption, i.e., bioavailability, of curcumin by means of an appropriate, suitable formulation. It is a further object of the invention to achieve a stable, homogeneous fine distribution of curcumin in the corresponding end products, such as dietary and nutritional supplements.
- The invention provides a micellar curcumin formulation, on the basis of which bioavailability that is at least 230 times higher in comparison to native curcumin has been established in a human study. The invention provides a solubilisate consisting of curcumin in a quantity of less than or equal to 10% by weight, preferably less than or equal to 7.5% by weight, particularly preferably 6% by weight, and at least one emulsifier having an HLB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin is between 5 nm and 40 nm, preferably between 6 nm and 20 nm, particularly preferably between 7 nm and 10 nm.
-
FIG. 1 shows photographs of curcumin formulation samples. - High loading of the micelles with curcumin may thus be advantageously achieved without the micelles bursting and the curcumin being released as sediment upon dilution with water.
- The transparent, completely stable water-soluble curcumin formulation according to the invention, without the above-mentioned auxiliary substances such as in soft and hard gelatin capsules, has stable transparency and also greatly improved bioavailability, independently of pH, in gelatin-free capsules (hard and/or soft) and in beverages or liquid, water-based end products. Products having such transparency and water solubility, but also in particular such a high bioavailability of the curcumin formulation, are in urgent demand by the relevant industry for innovative products as a capsule filling and as transparent curcumin beverages. To the knowledge of the inventor, a curcumin formulation which meets these requirements has not existed heretofore.
- The particularly small size of the micelles in the solubilisate according to the invention results in a clear, permanently transparent product. The narrow particle size distribution also contributes to this end, since the diameter distribution of the micelles ranges only from approximately 4 nm to approximately 30 nm.
- The particle size distribution of the micelles was measured according to the principle of dynamic light scattering in a 180° backscattering system, using laser light having a wavelength of 780 nm. Due to the small particle sizes, the formation of a liquid which is clear, in particular for perception by the human eye, is advantageously achieved. The clarity of the solubilisate may also be represented by its low turbidity.
- To this end, the following working hypothesis is used: The clearer an aqueous dilution of a solubilisate or some other formulation of curcumin, the better its solubilization. The better the solubilization, the better the bioavailability.
- The solubilisate according to the invention is further characterized in that the total curcuminoid concentration in human blood plasma, measured one hour after oral administration of 500 mg curcumin in the form of the solubilisate, is approximately
- 500 ng curcuminoid per ml plasma ±100 ng curcuminoid per ml plasma. In contrast, when native curcumin is taken orally in powdered form, only approximately 1.3 ng curcuminoid per ml plasma is achieved after one hour.
- The human study on which these values are based was conducted on 24 healthy persons between 19 and 29 years of age, who received a single oral dose of 500 mg native curcumin or curcumin in the form of the solubilisate according to the invention. Blood samples were withdrawn at various times over a period of 24 hours after the curcumin was taken. To minimize the possible concurrent influence of digested food, the test subjects were served standardized meals. One hour after taking the curcumin in native form, less than 1 nmol/l plasma was measured; 8 hours after administration, 2.4 nmol/l was measured; and 24 hours after administration, 2.4 nmol/l was measured. In contrast, for curcumin from the solubilisate according to the invention, one hour after administration, 1,964 nmol/l was measured in the blood plasma; 8 hours after administration, 307.1 nmol/l was measured; and 24 hours after administration, 67.7 nmol/l was measured. A solubilisate containing 66.5% by weight curcumin was used (the commercial product “6% NovaSOL Curcumin” of the applicant). Thus, the curcumin concentration in the blood plasma showed increases by a factor between 36 and 2800 as a result of the formulation as solubilisate according to the invention, compared to native curcumin.
- The area under the curve of the total curcumin concentration in the blood plasma (area under the total curcumin plasma concentration-time curve (AUC)), measured over a period of 24 hours, was 42.6 nmol h/L for administration of native curcumin, and 9,821.4 nmol h/L for administration of the solubilisate according to the invention. In somewhat generalized terms, it may be said that the plasma AUC of the curcumin solubilisate according to the invention over 24 hours is in the range of approximately 9,500 to approximately 10,000 nmol h/L.
- Accordingly, the bioavailability of the 66.5% curcumin solubilisate is much better than that of the native form. Viewed as the plasma AUC over 24 hours, the bioavailability as a result of the formulation according to the invention of the solubilisate is approximately 230 times higher.
- This may be deduced from the particularly low turbidity of the solubilisate, which may be understood as a type of indicator of the bioavailability. The turbidity of the solubilisate according to the invention is less than 30 FNU, preferably less than 20 FNU, and particularly preferably is in the range between 0.5 FNU and 2 FNU, determined by scattered light measurement with infrared light according to the requirements of the ISO 7027 standard at a dilution of the solubilisate in water in a ratio of 1:1000.
- The solubilisate according to the invention maintains this low turbidity after 24 hours storage at 21° C. and pH 7, as well as after 1 hour storage at 37° C. and pH 1.1, i.e., under storage conditions on the one hand at room temperature in aqueous dilution, and on the other hand, during passage through the stomach. Therefore, according to the present knowledge of the inventor, the curcumin in the solubilisate according to the invention is still present in the form of the stable, very small micelles even after passage through the stomach, and may therefore by absorbed particularly well in the further digestive tract.
- For experimentally determining the turbidity, the turbidity measuring devices are calibrated with a standard suspension. Thus, the indication is provided not in the form of the measured light intensity, but, rather, as the concentration of the calibration suspension. During the measurement of any given suspension, the indication thus signifies that the liquid in question has caused the same light scattering as the standard suspension of the indicated concentration. The internationally established turbidity standard is formazin. The most commonly used units are “FNU” (formazin nephelometric units). This is the unit that is used, for example, in water treatment for the measurement at 90° according to the requirements of the ISO 7072 standard. The turbidity of the solubilisate according to the invention is less than 30 FNU, preferably less than 20 FNU, and is particularly preferably in the range between 0.5 FNU and 2 FNU, determined by scattered light measurement with infrared light according to the requirements of the ISO 7027 standard at a dilution of the solubilisate in water in a ratio of 1:1000.
- Depending on the application, the solubilisate according to the invention may contain up to 5% by weight water and/or between 12% by weight and 20% by weight glycerin.
- It has advantageously been found that the solubilisate according to the invention may be easily provided in capsules for oral administration, since it does not attack the capsules. The invention thus also provides a capsule filled with the solubilisate, wherein the capsule may be formed as a soft gelatin capsule or hard gelatin capsule, or as a soft gelatin-free capsule or as a hard gelatin-free capsule.
- An additional administration form is a fluid containing the solubilisate according to the invention, wherein the fluid may be a food, a beverage, a cosmetic product such as a cream, lotion, or salve in particular, or a pharmaceutical product. In particular, the fluid may comprise an aqueous dilution of the solubilisate. The usability of the according to the invention in a fluid is not bound to its viscosity; the solubilisate may likewise be incorporated into hydrophilic as well as lipophilic media.
- Exemplary embodiments of solubilisates according to the invention are explained below.
- The particle size measurements were carried out using a ParticleMetrix NANOTRAC backscattering particle analyzer. The measuring principle is based on dynamic light scattering (DLS) in a 180° heterodyne backscattering system. In this geometry, a portion of the laser beam is mixed with the scattered light. This has the same positive effect with regard to the signal/noise ratio as the superimposition of all light wavelengths in a Fourier spectrometer. The color of the sample has no influence on the quality of the measurement. The measurements were carried out in a 1:1000 aqueous dilution. To this end, the solubilisate was dissolved in water with stirring. The solubilisate is soluble in water, in which it is completely clear. This solution is stable and transparent.
- Only 930 g polysorbate 80 and 70 g 95% curcumin powder are used for producing the solubilisate. The 70 g contains 95% curcumin, i.e., 66.5 g of curcumin.
- Commercially available preparations such as TEGO SMO 20 V, InCoPa, or Crillet 4/Tween 80-LQ-(SG), Croda, or Lamesorb SMO 80, Cognis are usable as polysorbate 80. Commercially available preparations may likewise be used as 95% curcumin powder, for example Oleoresin Turmeric 95% (curcumin powder), Jupiter Leys, or Curcumin BCM-95-SG, Eurochem, or Curcumin BCM-95-CG, Eurochem, or Curcuma Oleoresin 95%, Henry Lamotte.
- The polysorbate 80 is heated to approximately 48° C. to approximately 52° C. The curcumin powder is slowly added to the polysorbate 80, with stirring. During the addition of the curcumin powder, further heating to approximately 87° C. to approximately 91° C. is carried out. The resulting solubilisate is cooled to below approximately 60° C., and is then ready for filling.
- The solubilisate is yellow-orange to reddish, very dark, intensely colored, and transparent.
- The curcumin portion may be increased to approximately 10% by weight at the expense of the polysorbate 80 portion.
- Only 894 g polysorbate 20 and 106 g 95% curcumin powder are used for producing the solubilisate. The 106 g contains 95% curcumin, i.e., 100.7 g of curcumin.
- Commercially available preparations such as TEGO SML 20 V, InCoPa, or Tween 20, Crillet, 1-LQ-(SG), Croda, or Lamesorb SML 20, Cognis are usable as polysorbate 80.
- Commercially available preparations may likewise be used as 95% curcumin powder, for example Oleoresin Turmeric 95% (curcumin powder), Jupiter Leys, or Curcumin BCM-95-SG, Eurochem, or Curcumin BCM-95-CG, Eurochem, or Curcuma Oleoresin 95%, Henry Lamotte.
- The polysorbate 20 is heated to approximately 63° C. to approximately 67° C. The curcumin powder is slowly added to the polysorbate 20, with stirring. During the addition of the curcumin powder, further heating to approximately 83° C. to approximately 87° C. is carried out. The resulting solubilisate is slowly cooled to below approximately 45° C., and is then ready for filling.
- The solubilisate is yellow-orange to reddish, very dark, intensely colored, and transparent.
- The curcumin portion may be varied at the expense of the polysorbate 80 portion.
- Photographs of samples of various curcumin formulations are shown in appended
FIG. 1 . The left side of the illustration shows the samples 24 hours after addition to water at a temperature of 21° C., under neutral conditions (pH 7). The right side of the illustration shows the samples under physiological conditions 1 hour after addition to water at a temperature of 37° C., under conditions as in the stomach (pH 1.1). In each case, enough water was added to the starting preparations to give a curcumin concentration of 11.4 g/L in the illustrated sample. - In particular, the following formulations were compared:
- Sample A
- Curcumin extract, native form, powder, 95% curcumin (BCM 95). 12 g of the powder was introduced into 1 liter of water.
- Sample B
- 17.5% curcumin micronisate, powder, RAPS. 65.1 g of the powder was introduced into 1 liter of water.
- Sample C
- 13% curcumin-formulation, powder, Wacker Chemie. 87. 7 g of the powder was introduced into 1 liter of water.
- Sample D
- Curcumin solubilisate according to the invention according to Example 1. 200 g of the liquid solubilisate was introduced into 1 liter of water.
- Sedimentation and phase separation were observed for samples A, B, and C, at room temperature under neutral conditions and also at 37° C. and acidic conditions,
- whereas sample D was clear and homogeneous. The solubilisate according to the invention also showed no phase separation and no sedimentation over the entire temperature range from −20° C. to 100° C. Furthermore, sample D showed a fairly intense red coloring, at room temperature under neutral conditions and also at 37° C. and acidic conditions, as the result of which the sample appears much darker in a black and white photograph than samples A, B, and C, which have a yellowish-orange color.
- It is apparent to one skilled in the art that the invention is not limited to the exemplary embodiments described above, but, rather, may be varied in numerous ways. In particular, the features of the individual exemplary embodiments may also be combined with one another or interchanged with one another.
Claims (12)
1. Solubilisate composed of
curcumin in a quantity of less than or equal to 10% by weight, preferably less than or equal to 7.5% by weight, particularly preferably 6% by weight, and
at least one emulsifier having an HlB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80,
wherein the average diameter of the micelles loaded with curcumin is between 5 nm and 40 nm, preferably between 6 nm and 20 nm, particularly preferably between 7 nm and 10 nm.
2. Solubilisate according to claim 1 , characterized in that the width of the diameter distribution of the micelles ranges from approximately 4 nm to approximately 30 nm.
3. Solubilisate according to one of the preceding claims,
characterized in that the total curcuminoid concentration in human blood plasma, measured one hour after oral administration of 500 mg curcumin in the form of the solubilisate according to one of the preceding claims, is approximately 500 ng curcuminoid per ml plasma ±100 ng curcuminoid per ml plasma.
4. Solubilisate according to one of the preceding claims, characterized in that the total curcuminoid concentration in human blood plasma, measured over a period of 24 hours as the area under the total curcumin plasma concentration-time curve (area under the total curcumin plasma concentration-time curve AUC), is in the range of approximately 9,500 to approximately 10,000 nmol h/l.
5. Solubilisate according to one of the preceding claims, characterized in that the turbidity of the solubilisate is less than 30 FNU, preferably less than 20 FNU, and particularly preferably is in the range between 0.5 FNU and 2 FNU, determined by scattered light measurement with infrared light according to the requirements of the ISO 7027 standard at a dilution of the solubilisate in water in a ratio of 1:1000.
6. Solubilisate according to one of the preceding claims, characterized in that the turbidity of the solubilisate after 24 hours storage at 21° C. and pH 7 is less than 30 FNU, preferably less than 20 FNU, and particularly preferably is in the range between 0.5 FNU and 2 FNU, determined by scattered light measurement with infrared light according to the requirements of the ISO 7027 standard at a dilution of the solubilisate in water in a ratio of 1:1000.
7. Solubilisate according to one of the preceding claims, characterized in that the turbidity of the solubilisate after 1 hour storage at 37° C. and pH 1.1 is less than 30 FNU, particularly preferably less than 20 FNU, and particularly preferably is in the range between 0.5 FNU and 2 FNU, determined by scattered light measurement with infrared light according to the requirements of the ISO 7027 standard at a dilution of the solubilisate in water in a ratio of 1:1000.
8. Solubilisate according to one of the preceding claims, characterized in that the solubilisate contains up to 5% by weight water.
9. Solubilisate according to one of the preceding claims, characterized in that the solubilisate contains between 12% by weight and 20% by weight glycerin.
10. Capsule filled with a solubilisate according to one of the preceding claims, characterized in that the capsule is formed as a soft gelatin capsule or hard gelatin capsule, or as a soft gelatin-free capsule or as a hard gelatin-free capsule.
11. Fluid containing a solubilisate according to one of claims 1 to 10 , characterized in that the fluid is selected from the group comprising foods, beverages, cosmetics, and pharmaceutical products.
12. Fluid according to claim 11 , characterized in that the fluid comprises an aqueous dilution of the Solubilisate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/698,389 US20220202713A1 (en) | 2012-12-19 | 2022-03-18 | Curcumin Solubilisate |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE202012012130.8 | 2012-12-19 | ||
DE202012012130.8U DE202012012130U1 (en) | 2012-12-19 | 2012-12-19 | Curcuminsolubilisat |
PCT/EP2013/001427 WO2014094921A1 (en) | 2012-12-19 | 2013-05-15 | Curcumin solubilisate |
US201514653560A | 2015-06-18 | 2015-06-18 | |
US17/698,389 US20220202713A1 (en) | 2012-12-19 | 2022-03-18 | Curcumin Solubilisate |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/001427 Continuation WO2014094921A1 (en) | 2012-12-19 | 2013-05-15 | Curcumin solubilisate |
US14/653,560 Continuation US11311483B2 (en) | 2012-12-19 | 2013-05-15 | Curcumin solubilisate |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220202713A1 true US20220202713A1 (en) | 2022-06-30 |
Family
ID=48628594
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/653,560 Active US11311483B2 (en) | 2012-12-19 | 2013-05-15 | Curcumin solubilisate |
US17/698,389 Abandoned US20220202713A1 (en) | 2012-12-19 | 2022-03-18 | Curcumin Solubilisate |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/653,560 Active US11311483B2 (en) | 2012-12-19 | 2013-05-15 | Curcumin solubilisate |
Country Status (19)
Country | Link |
---|---|
US (2) | US11311483B2 (en) |
EP (1) | EP2934185B1 (en) |
JP (1) | JP6324989B2 (en) |
KR (2) | KR20180007005A (en) |
CN (2) | CN109330980B (en) |
BR (1) | BR112015014654B1 (en) |
CY (1) | CY1118432T1 (en) |
DE (1) | DE202012012130U1 (en) |
DK (1) | DK2934185T3 (en) |
ES (1) | ES2609504T3 (en) |
HK (1) | HK1211801A1 (en) |
MY (1) | MY175753A (en) |
PL (1) | PL2934185T3 (en) |
PT (1) | PT2934185T (en) |
RS (1) | RS55490B1 (en) |
RU (1) | RU2615815C2 (en) |
SI (1) | SI2934185T1 (en) |
UA (1) | UA113573C2 (en) |
WO (1) | WO2014094921A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11786484B2 (en) | 2018-07-11 | 2023-10-17 | Aquanova Ag | Xanthohumol solubilizate |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108697668B (en) * | 2015-08-28 | 2022-11-04 | 康霈生技股份有限公司 | Pharmaceutical composition for reducing local fat and use thereof |
JP2019517574A (en) * | 2016-04-07 | 2019-06-24 | メドクリア ヘルスケア プライベート リミテッドMedclear Healthcare Private Limited | Preparation of curcuminoid in water (liquid) and its process |
CA3027450C (en) * | 2016-06-14 | 2023-08-29 | Aquanova Ag | Resveratrol solubilisation product |
HUE049304T2 (en) * | 2016-06-14 | 2020-09-28 | Aquanova Ag | Resveratrol solubilisation product for pharmaceutical purposes |
EP3290026A1 (en) | 2016-09-06 | 2018-03-07 | Athenion AG | Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents |
IT201700045343A1 (en) * | 2017-04-26 | 2018-10-26 | Micro Sphere Sa | PROCESS FOR THE PREPARATION OF A FOOD AND SUPPLEMENTARY SUPPLEMENTER SO OBTAINED |
KR102573152B1 (en) * | 2017-07-11 | 2023-09-01 | 아쿠아노바 아게 | Solubilisate with curcumin and optionally at least one other active substance |
WO2019011414A1 (en) * | 2017-07-11 | 2019-01-17 | Aquanova Ag | Solubilisate with curcumin and boswellia |
CN111163806A (en) | 2017-07-11 | 2020-05-15 | 阿奎诺瓦股份公司 | Solubilized product comprising curcumin, boswellia and xanthohumol |
WO2019011415A1 (en) * | 2017-07-11 | 2019-01-17 | Aquanova Ag | Solubilisate with curcumin, xanthohumol and licorice root extract |
EP3511325A1 (en) | 2018-01-11 | 2019-07-17 | MetrioPharm AG | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione |
DE102018101778A1 (en) * | 2018-01-26 | 2019-08-01 | Lts Lohmann Therapie-Systeme Ag | Multilayer oral thin film |
EP3536332A1 (en) | 2018-03-07 | 2019-09-11 | Athenion AG | Krill oil for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents |
BR112020026362A2 (en) * | 2018-07-11 | 2021-03-30 | Aquanova Ag | SOLUBILIZED WITH CURCUMIN AND AT LEAST ONE CANABINOID AS AN ADDITIONAL ACTIVE SUBSTANCE |
WO2020011402A1 (en) * | 2018-07-11 | 2020-01-16 | Aquanova Ag | Xanthohumol solubilisate |
TR201910337A2 (en) | 2019-07-10 | 2021-01-21 | Mehmet Nevzat Pisak | CURCUMINOID ORAL COMPOUNDS WITH HIGH RESOLUTION AND BIO-ADJUSTMENT |
US20210060166A1 (en) * | 2019-07-29 | 2021-03-04 | Horacio Astudillo de la Vega | Method for the preparation of a 1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione system in polysorbates for the formation of micelles in an aqueous medium aimed at the properties of the bioavailability of curcuminoids |
DE202019104734U1 (en) * | 2019-08-29 | 2020-12-01 | Aquanova Ag | Folic acid solubilisate |
AU2020366237A1 (en) * | 2019-10-18 | 2022-04-14 | Quicksilver Scientific, Inc. | Self-microemulsifying multi-deliverable systems |
EP4090173A1 (en) * | 2020-01-13 | 2022-11-23 | Rrw B.V. | Aqueous solution of a lipophilic compound |
EP3919046A1 (en) | 2020-06-02 | 2021-12-08 | Athenion AG | Method for solubilizing natural, endogenous and synthetic cannabinoids |
EP4186497A1 (en) | 2021-11-26 | 2023-05-31 | Dorian Bevec | Alpha lipoic acid, epigallocatechin 3-gallate, and curcumin as a medicament for the treatment of arthritis or sars-cov-2 infection |
WO2024057288A1 (en) | 2022-09-16 | 2024-03-21 | Bausch Health Ireland Limited | Methods for treating acne and skin oiliness with tazarotene |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3886294A (en) | 1973-03-12 | 1975-05-27 | Hoffmann La Roche | Carotenoid coloring compositions and preparation thereof |
US6056971A (en) * | 1996-07-24 | 2000-05-02 | Biosytes Usa, Inc. | Method for enhancing dissolution properties of relatively insoluble dietary supplements and product incorporating same |
US6673380B2 (en) * | 1998-11-17 | 2004-01-06 | Mcneil-Ppc, Inc. | Fortified confectionery delivery systems and methods of preparation thereof |
ES2324400T3 (en) | 2001-02-11 | 2009-08-06 | Aquanova Ag | PROCEDURE FOR THE PRODUCTION OF A CONCENTRATE OF ISOFLAVONAS. |
DE10133305B4 (en) | 2001-07-12 | 2004-06-03 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Ubiquinone concentrate |
DE10158447B4 (en) * | 2001-11-30 | 2005-02-10 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Ascorbic Solubilisate |
JP4206923B2 (en) * | 2003-12-26 | 2009-01-14 | 三栄源エフ・エフ・アイ株式会社 | Method for preparing aqueous turmeric pigment preparation |
DE202004003241U1 (en) * | 2004-02-27 | 2005-07-14 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Solubilized, high bioavailability vitamin product, comprising vitamin A (or its ester) and excess emulsifier, especially polysorbate 80 |
JP2005328839A (en) * | 2004-04-19 | 2005-12-02 | Microcel:Kk | Solubilized liquid of hardly-soluble component and method for producing the same |
DE502004009901D1 (en) * | 2004-07-22 | 2009-09-24 | Aquanova Ag | SOLUBILISATES OF ESSENTIAL OILS AND OTHER SUBSTANCES |
CN100352430C (en) * | 2005-03-09 | 2007-12-05 | 山东大学 | Self microemulsifying preparation of curcumin and its preparing process |
US20060275516A1 (en) * | 2005-06-02 | 2006-12-07 | Ram A N S | Compositions and methods for the treatment of allergic rhinitis |
US20080220102A1 (en) * | 2005-07-08 | 2008-09-11 | Dariush Behnam | Solubilsation Products of an Active Ingredient Extract |
WO2008101344A1 (en) | 2007-02-22 | 2008-08-28 | Peter Tomlinson | Soluble bioactive lipophilic compounds compositions |
CN101543486A (en) * | 2008-03-25 | 2009-09-30 | 福建医科大学 | Application of tetrahydrocurcumin in preparing antidepressant and method for preparing solid dispersion of tetrahydrocurcumin |
CN101361713B (en) * | 2008-09-08 | 2010-08-25 | 山东大学 | Curcumin nano crystallization preparation and preparation method thereof |
CN102202652A (en) | 2008-11-17 | 2011-09-28 | 莱拉制药用品私营有限责任公司 | A process for nanoemulsification of curcumin and derivatives of curcumin |
AU2009329035A1 (en) * | 2008-12-01 | 2011-06-23 | Laila Pharmaceuticals Pvt. Ltd. | Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof |
ES2602812T3 (en) * | 2008-12-01 | 2017-02-22 | Aquanova Ag | Micellarly integrated oxidation protection for natural dyes |
CN102405046B (en) * | 2009-03-20 | 2014-07-02 | 百欧特瑞股份公司 | Pharmaceutical composition presenting anti-inflammatory properties |
EP2410999A4 (en) * | 2009-03-23 | 2012-04-18 | Laila Pharmaceuticals Pvt Ltd | Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions |
JP2010265223A (en) | 2009-05-15 | 2010-11-25 | National Cardiovascular Center | Inhibitor of anaerobic fermentation |
DE202009016292U1 (en) * | 2009-12-01 | 2011-04-07 | Aquanova Ag | Emulsifying composition for water-soluble solubilisates of hydrophobic compounds |
US8835509B2 (en) * | 2010-05-31 | 2014-09-16 | Arbro Pharmaceuticals Ltd. | Self emulsifying drug delivery system for a curcuminoid based composition |
CA2828253C (en) | 2011-02-25 | 2016-10-18 | South Dakota State University | Polymer conjugated protein micelles |
CN103491964A (en) * | 2011-03-08 | 2014-01-01 | 扎里卡斯药品有限公司 | Solid dispersion formulations and methods of use thereof |
-
2012
- 2012-12-19 DE DE202012012130.8U patent/DE202012012130U1/en not_active Expired - Lifetime
-
2013
- 2013-05-15 RU RU2015129577A patent/RU2615815C2/en active
- 2013-05-15 PL PL13729247T patent/PL2934185T3/en unknown
- 2013-05-15 WO PCT/EP2013/001427 patent/WO2014094921A1/en active Application Filing
- 2013-05-15 JP JP2015548242A patent/JP6324989B2/en active Active
- 2013-05-15 DK DK13729247.0T patent/DK2934185T3/en active
- 2013-05-15 KR KR1020187000630A patent/KR20180007005A/en not_active Application Discontinuation
- 2013-05-15 CN CN201811453446.4A patent/CN109330980B/en active Active
- 2013-05-15 UA UAA201507032A patent/UA113573C2/en unknown
- 2013-05-15 US US14/653,560 patent/US11311483B2/en active Active
- 2013-05-15 EP EP13729247.0A patent/EP2934185B1/en active Active
- 2013-05-15 CN CN201380067238.XA patent/CN104902765A/en active Pending
- 2013-05-15 PT PT137292470T patent/PT2934185T/en unknown
- 2013-05-15 MY MYPI2015702012A patent/MY175753A/en unknown
- 2013-05-15 BR BR112015014654-6A patent/BR112015014654B1/en active IP Right Grant
- 2013-05-15 RS RS20161168A patent/RS55490B1/en unknown
- 2013-05-15 KR KR1020157016542A patent/KR101983332B1/en active IP Right Grant
- 2013-05-15 SI SI201330471A patent/SI2934185T1/en unknown
- 2013-05-15 ES ES13729247.0T patent/ES2609504T3/en active Active
-
2015
- 2015-11-09 HK HK15111002.6A patent/HK1211801A1/en unknown
-
2017
- 2017-01-05 CY CY20171100017T patent/CY1118432T1/en unknown
-
2022
- 2022-03-18 US US17/698,389 patent/US20220202713A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11786484B2 (en) | 2018-07-11 | 2023-10-17 | Aquanova Ag | Xanthohumol solubilizate |
Also Published As
Publication number | Publication date |
---|---|
UA113573C2 (en) | 2017-02-10 |
EP2934185B1 (en) | 2016-10-12 |
WO2014094921A1 (en) | 2014-06-26 |
KR101983332B1 (en) | 2019-09-03 |
EP2934185A1 (en) | 2015-10-28 |
RU2615815C2 (en) | 2017-04-11 |
PT2934185T (en) | 2017-01-18 |
BR112015014654A2 (en) | 2017-07-11 |
RU2015129577A (en) | 2017-01-24 |
CN109330980B (en) | 2021-12-21 |
DE202012012130U1 (en) | 2014-03-21 |
JP2016505579A (en) | 2016-02-25 |
MY175753A (en) | 2020-07-08 |
KR20150095698A (en) | 2015-08-21 |
US20160128939A9 (en) | 2016-05-12 |
DK2934185T3 (en) | 2017-01-23 |
JP6324989B2 (en) | 2018-05-16 |
ES2609504T3 (en) | 2017-04-20 |
RS55490B1 (en) | 2017-04-28 |
US20150342881A1 (en) | 2015-12-03 |
SI2934185T1 (en) | 2017-02-28 |
CY1118432T1 (en) | 2017-06-28 |
CN109330980A (en) | 2019-02-15 |
CN104902765A (en) | 2015-09-09 |
PL2934185T3 (en) | 2017-07-31 |
BR112015014654B1 (en) | 2020-08-18 |
US11311483B2 (en) | 2022-04-26 |
HK1211801A1 (en) | 2016-06-03 |
KR20180007005A (en) | 2018-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220202713A1 (en) | Curcumin Solubilisate | |
FI3651804T3 (en) | Solubilisate with curcumin, boswellia, and xanthohumol | |
US20170189446A1 (en) | Emulsion of Carotenoids and Ocular Antioxidants | |
US20170326077A1 (en) | Homogenous composition and methods of making the same | |
FI3820529T3 (en) | Solubilisate with curcumin and at least the cannabinoid thc as a further active agent | |
CN109562066B (en) | Resveratrol solubilized product for pharmaceutical purposes | |
US20220175678A1 (en) | Formulations for encapsulation and bioavailability improvement of bioactive compounds based on natural plant based materials | |
CN109641060B (en) | Resveratrol solubilisation product | |
US11786484B2 (en) | Xanthohumol solubilizate | |
Kharat | Design and Fabrication of Colloidal Delivery Systems to Encapsulate and Protect Curcumin: An Important Hydrophobic Nutraceutical | |
RU2777185C1 (en) | Solubilisate with curcumin and at least one thc cannabinoid as an additional active substance | |
WO2023177313A1 (en) | A composition forming stable monodisperse emulsions in water | |
KR102573152B1 (en) | Solubilisate with curcumin and optionally at least one other active substance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: AQUANOVA AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BEHNAM, DARIUSH;REEL/FRAME:060291/0934 Effective date: 20150730 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |